Clinical Trial Detail

NCT ID NCT01828476
Title Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
Recruitment Terminated
Gender male
Phase Phase II
Variant Requirements no
Sponsors Rutgers, The State University of New Jersey
Indications

prostate cancer

Therapies

Hydroxychloroquine

Abiraterone + Navitoclax

Age Groups: adult

No variant requirements are available.